Related Experiment Video
Updated: Jun 25, 2026

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
Published on: August 18, 2015
What's new in stroke? The top 10 studies of 2006-2008. Part II
1Vascular Neurology, Department of Neurology, University of Texas Health Science Center, San Antonio, TX 78229, USA. hartr@uthscsa.edu
Insights
The ABCD2 score predicts stroke risk after transient ischemic attack. High-dose atorvastatin, IV tPA, and warfarin offer stroke prevention and treatment benefits, though carotid stenting
Area of Science:
- Neurology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Stroke prevention and treatment are critical public health concerns.
- Recent clinical trials have aimed to refine management strategies for stroke and transient ischemic attack (TIA).
- Understanding the efficacy and safety of various interventions is essential for improving patient outcomes.
Purpose of the Study:
- To review six influential studies from 2006-2008 impacting stroke and TIA clinical management.
- To summarize key findings regarding stroke risk stratification, prevention, and treatment.
Main Methods:
- Review of six significant clinical studies published between 2006 and 2008.
- Analysis of data related to stroke risk scores, pharmacological interventions, and revascularization procedures.
Main Results:
- The ABCD2 score accurately stratifies 7-day stroke risk post-TIA (high 12%, moderate 6%, low 1%).
- High-dose atorvastatin reduces recurrent stroke but may increase CNS hemorrhage (SPARCL).
- Intravenous tissue plasminogen activator benefits selected patients within 3-4.5 hours of ischemic stroke (ECASS III).
- Adjusted-dose warfarin is superior and safe for elderly atrial fibrillation patients (BAFTA).
- Optimal role of carotid angioplasty/stenting versus endarterectomy remains uncertain (SAPPHIRE, EVA-3S, SPACE).
- Enoxaparin is an effective alternative to unfractionated heparin for VTE prevention post-stroke (PREVAIL).
Conclusions:
- Recent studies provide crucial insights into optimizing stroke prevention and treatment.
- The ABCD2 score aids in risk stratification for TIA patients.
- Pharmacological interventions like atorvastatin, tPA, and warfarin have defined roles in stroke management.
- Further research is needed to clarify the best approach for carotid revascularization.
Abstract:
Six studies from 2006-2008 that have influenced clinical management of stroke and threatened stroke are presented. The ABCD2 score effectively stratifies the short-term risk of stroke following transient ischemic attack into those with a high (12%), moderate (6%), and low (1%) 7-day stroke risk. High-dose atorvastatin reduces recurrent stroke in patients with recent stroke, but probably slightly increases central nervous system hemorrhage (SPARCL). Intravenous tissue plasminogen activator is of overall benefit to selected patients when given 3 to 4.5 hours after ischemic stroke onset (ECASS III). Adjusted-dose warfarin is far superior to aspirin and is relatively safe for very old people with atrial fibrillation (BAFTA). Despite results from 3 recent randomized trials (SAPPHIRE, EVA-3S and SPACE) the optimal role of carotid angioplasty/stenting vs. endarterectomy remains unclear. Enoxaparin once daily is an efficacious alternative to unfractionated heparin twice daily for prevention of venous thromboembolism after acute ischemic stroke (PREVAIL). These recent studies add important pieces to the complex puzzle of optimal stroke prevention and treatment.
Related Concept Videos
Stroke: Introduction and Types
Regulation of Stroke Volume
Preload refers to the degree of stretch on the heart before it contracts. It's analogous to the stretching of a rubber band; the more it's stretched, the more forcefully it snaps back. This concept is encapsulated in the Frank-Starling law of the...
Ischemic Stroke l: Introduction
Ischemic Stroke ll: Pathophysiology
Hemorrhagic Stroke l: Introduction
Hemorrhagic Stroke ll: Pathophysiology
